Table 21.
First-line | Escitalopram, fluvoxamine, fluvoxamine CR, paroxetine, paroxetine CR, pregabalin, sertraline, venlafaxine XR |
---|---|
Second-line | Alprazolam, bromazepam, citalopram, clonazepam, gabapentin, phenelzine |
Third-line | Atomoxetine, bupropion SR, clomipramine, divalproex, duloxetine, fluoxetine, mirtazapine, moclobemide, olanzapine, selegiline, tiagabine, topiramate |
Adjunctive therapy |
Third-line: aripiprazole, buspirone, paroxetine, risperidone Not recommended: clonazepam, pindolol |
Not recommended | Atenolol*, buspirone, imipramine, levetiracetam, propranolol*, quetiapine |
CR = controlled release; SR = sustained release; XR = extended release.
*Beta-blockers have been successfully used in clinical practice for performance situations such as public speaking.
Note: although there is limited evidence for citalopram in SAD, it is likely as effective as the other SSRIs, in contrast there are negative trials of fluoxetine in SAD suggesting it may be less effective than other SSRIs [382,449].